New Issue: Orbital Catastrophe Ahead? Read Now

New ‘Cicada’ COVID variant is spreading in the U.S.—here’s what to know

Infections of the BA.3.2 variant of the COVID-causing coronavirus are still at very low levels, but experts are concerned it may be resistant to immunity from vaccines or prior infection

Illustration of a Sars COV-2 virus

A new variant of SARS-CoV-2, the virus that causes COVID, dubbed "Cicada" is circulating.

Koto_feja/Getty Images

Join Our Community of Science Lovers!

A new variant of the virus that causes COVID is spreading in the U.S. The “Cicada” variant, officially known as BA.3.2, was first detected in South Africa in November 2024. But infection rates in the U.S. have been slowly rising since last fall, according to a recent Centers for Disease Control and Prevention report.

Cicada is notable because it has a highly mutated genetic sequence that some experts fear could enable it to evade some of our immunity from vaccination or a past COVID infection. And it appears to be primarily infecting kids—though it's not causing more severe disease.

The variant had been detected in 23 countries as of February, the CDC’s report states. The agency’s genomic surveillance program first detected the variant in the U.S. last June in a traveler from the Netherlands. It later showed up in nasal swabs from four travelers, three samples of airplane wastewater, five clinical samples from patients and 132 wastewater samples from 25 states, according to the report, which was published on March 19 in the CDC’s Morbidity and Mortality Weekly Report.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The BA.3.2 variant has around 70 to 75 mutations in the genetic sequence of its spike protein (the protein the virus uses to infect cells) relative to the strains that were included in last fall’s COVID vaccines: the JN.1 variant and its descendent LP.8.1. And in laboratory studies, the Cicada variant was able to evade antibodies, “highlighting the need for ongoing genomic surveillance and observational evaluations of vaccine and antiviral effectiveness,” the report’s authors write.

Still, Cicada accounts for only a tiny fraction of COVID cases in the U.S.—fewer than 0.2 percent of sequences collected from December 1, 2025, through February 11, 2026. And it hasn’t been linked with higher COVID cases overall.

While COVID is no longer as serious as it was during the pandemic’s early years, it nonetheless caused an estimated 390,000 to 550,000 hospitalizations and 45,000 to 64,000 deaths during the 2024–2025 respiratory virus season—and preliminary estimates of 110,000 to 210,000 hospitalizations and 12,000 to 37,000 deaths between October 1, 2025, and March 21, 2026—according to CDC data.

Editor's Note (4/3/26): This article was added after publication to include information about the variant's prevalence in children.

Tanya Lewis was formerly senior desk editor for health and medicine at Scientific American. She wrote and edited stories for the website and print magazine on topics ranging from COVID to organ transplants. She also appeared on Scientific American’s podcast Science Quickly and wrote Scientific American’s weekly Health & Medicine newsletter. She held a number of positions over her nearly 10 years at Scientific American, including health editor, assistant news editor and associate editor at Scientific American Mind. Previously, she has written for outlets that include Insider, Wired, Science News and others. She has a degree in biomedical engineering from Brown University and one in science communication from the University of California, Santa Cruz. Follow her on Bluesky @tanyalewis.bsky.social

More by Tanya Lewis

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe